Rankings
▼
Calendar
PCVX Q4 2021 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena
PCVX
Vaxcyte, Inc.
$9B
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$30M
Net Income
-$29M
EPS (Diluted)
$-0.52
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$51M
Free Cash Flow
-$52M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$324M
Total Liabilities
$40M
Stockholders' Equity
$284M
Cash & Equivalents
$69M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$30M
-$19M
-53.4%
Net Income
-$29M
-$21M
-37.7%
← FY 2021
All Quarters
Q1 2022 →